Use of Clinical Global Impressions‐Severity (CGI‐S) to assess response to antidepressant treatment in patients with treatment‐resistant depression
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: This post-hoc analysis evaluated the agreement between Clinical Global Impressions-Severity (CGI-S) score- and Montgomery-Åsberg Depression Rating Scale (MADRS) total score-based assessment of response in patients with treatment-resistant depression (TRD) treated with esketamine nasal spray plus a newly initiated oral antidepressant (ESK-NS + AD). Methods: Data were analyzed from a phase 3, randomized, double-blind study (TRANSFORM-2) of flexibly dosed esketamine or placebo nasal spray plus a newly initiated oral-AD in adults with moderate-to-severe TRD. Patients with ≥50% reduction in MADRS from baseline at the end of the 4-week acute treatment phase were defined as responders. For the CGI-S-based assessment of response, patients with ≥2 points decrease from baseline or a CGI-S score of ≤3 (mildly depressed to normal) were considered responders. Cohen's kappa coefficient was calculated to assess level of agreement between MADRS and CGI-S-based assessments. Results: At the end of 4-week treatment, the proportion of responders among all study patients (n=201) was similar when assessed using the MADRS (61%) and CGI-S (62%) methods, with substantial agreement (Cohen's kappa=0.76; sensitivity=92%; specificity=84%) between both methods. When restricting analysis to ESK-NS + AD-treated patients (n=101) who had a higher response rate (on MADRS: 69%; on CGI-S: 68%), the agreement remained substantial (Cohen's kappa=0.75; sensitivity=91%; specificity=84%). Conclusion: The CGI-S may be a practical and reliable alternative to the MADRS to assess response to ESK-NS + AD in patients with TRD and can be used in real-world practice to support informed treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 5×
“tionnaire (each item yields a score of 0 to 6), is a validated, clinician-rated measure of depression designed to measure depression severity and to detect changes due to antidepressant treatment in patients with MDD.(6) It is one of the most”
BackgroundMethodInfluentialThe clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,759
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 3×
“This post-hoc analysis was based on data from over 200 adult patients with the same diagnosis (and definition) of TRD participating in a phase 3 clinical study from the registration program of esketamine nasal spray, representing a relatively homogenous population for assessment.(17) Furthermore, the analysis included…”
MethodInfluentialSelf-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Using Measurement-Based Care to Enhance Any Treatment
Scott, K., & Lewis, C. C. (2015) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2014.01.010 · Cited by 461 · cited 1×
“Introduction Measurement-based care (MBC) is a critical component of an evidence-based decision support framework that guides patient treatment.(1) In mental health clinical practice, MBC approaches have been designed to provide systematic,”
BackgroundWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
A Comparison of Depression Rating Scales
Kearns, N. P., Cruickshank, C. A., McGuigan, K. J., Riley, S. A., Shaw, S. P., & Snaith, R. P. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.141.1.45 · Cited by 271 · cited 1×
“a research instrument usually takes approximately 20–40 minutes to administer and therefore may not be feasible for clinicians to use in their routine practice.(6,8) By contrast, the Clinical Global Impressions-Severity (CGI-S) is a single-item, 7-point scale designed to assess global impression of severity rather tha…”
MethodMeasurement-Based Care in Psychiatric Practice: A Policy Framework for Implementation
Harding, K. J. K., Rush, A. J., Arbuckle, M., Trivedi, M. H., & Pincus, H. A. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06282whi · Cited by 175 · cited 1×
“Given the variety of rating scales, using clinically and practically relevant measures that could potentially lower the burden of time associated with assessment is of great importance.(19,20) The MADRS has been used in pivotal clinical studies of antidepressants; however, its adoption in clinical practice is uncommon.”
Method
Research works printed but not linked: 2
- Busner, 2007, Psychiatry, 4, 28
- 1976, ECDEU Assessment Manual for Psychopharmacology
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Lipton, R. B., Campos, V. R., Arie, Z. R.-B., Galić, M., Mitsikostas, D. D., Tassorelli, C., Denysenko, L., & Cohen, J. M. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0806 · Cited by 35
Espinosa, V., Valiente, R. M., García-Escalera, J., Chorot, P., Arnáez, S., Schmitt, J. C., & Sandín, B. (2024) · Behaviour Research and Therapy · doi:10.1016/j.brat.2024.104560 · Cited by 16
Gutiérrez, G., Kang, M. J. Y., & Vázquez, G. H. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115865 · Cited by 18
“All data generated or analyzed during this study is available as needed upon reasonable request.”
MethodJiao, L., Chen, T., Huang, Y., & Huang, X. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1397706 · Cited by 13
Goodman, M. S., Trevizol, A. P., Konstantinou, G., Boivin-Lafleur, D., Brender, R., Downar, J. H., Kaster, T. S., Knyahnytska, Y., Vila‐Rodriguez, F., Voineskos, D., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-02007-w · Cited by 10
Park, H. Y., Jang, Y., Hong, A., Yoon, E., & Yoon, I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2482123 · Cited by 6
Kolstad, J., Zoppo, C. T., Johnston, J. M., D’Souza, P., Kühn, A. L., Vardar, Z., Peker, A., Hader, A., Celik, H., Lewis, C. J., et al. (2025) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2025.109025 · Cited by 6
Reif, A., Anıl, Y. A., Bitter, I., Buyze, J., Frey, R., Fu, D. J., Godinov, Y., Haggström, L., Kambarov, Y., Nielsen, R., et al. (2026) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2026.112801 · Cited by 4
Waisbren, S. E., Christ, S. E., Bilder, D. A., Bjoraker, K., Bolton, S., Chamberlin, S., Grant, M., Janzen, D. M., Katz, R., Lubliner, E., et al. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108555 · Cited by 3
Machine learning based seizure classification and digital biosignal analysis of ECT seizures
Kayser, M., Hurlemann, R., Philipsen, A., Freundlieb, N., & Kiebs, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-88238-3 · Cited by 2
“Patients who had experienced a decrease of ≥ 2 points from baseline or achieved a CGI-S score of ≤ 3 were deemed responders 37 .”
Putri, L. A., Elvira, S. D., Agiananda, F., & Lukman, P. R. (2024) · Asia Pacific Journal of Counselling and Psychotherapy · doi:10.1080/21507686.2024.2375230 · Cited by 3
“The CGI-I is especially useful in detecting clinical improvement across diverse patient populations and psychiatric disorders (Khan et al., 2002; Leucht & Engel, 2006; Morrens et al., 2022).”
Ryan, W. C., & Heifets, B. D. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2421895 · Cited by 7
Impact of difficult-to-treat depression for patients and society: a real-world study
Benavente, S., Parra, A., López‐Castromán, J., Conejero, I., Alonso-Torres, P., López, T. C., Arteaga, P. C., & Baca‐García, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1702137 · Cited by 1
Landau, C., Getty, P., Gruler, C., Stadje, R., Arampatzi, S., Mandal, A., Goel, A., Gurevych, I., Reif, A., & Grimm, O. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1616955 · Cited by 2
“The instrument has been proven to be a readily understood and practical measurement tool which is well applicable in the clinical practice (49) and has been used in different mental disorders including affective and psychotic disorders (50, 51).”
Feyder, M. T., Stimpson, K. H., Geoly, A. D., Ford, T. J., Maron‐Katz, A., Lutkenhoff, E., Bota, R. G., Carreon, D. M., Muir, O. S., MACMILLAN, C. M., et al. (2026) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2026.100184 · Cited by 1
“Clinically meaningful benefit was defined as a reduction in the CGI-S by 1 or more points [32,33].”
Hernandorena, C. V., Gilmar, G., Casimiro, C. A., & Vázquez, G. H. (2023) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2023.100620
Lenouvel, E., Tobias, S., Muehlbauer, V., Dallmeier, D., Denkinger, M. D., Klöppel, S., & Schönfeldt‐Lecuona, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4767641
Liu, Z., Sun, L., Sun, F., Cui, S. F., Zhang, Y., Wang, J., Zhang, Z., Sun, L., Yang, R., Yao, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-76183-6 · Cited by 2
“The severity of the disease using the Clinical Global Impression Severity Scale (CGI-S) 28 .”
MethodJha, M. K., Teeple, A., Shepherd, J., Gillespie, A., Grant, N., Mortimer, A., Kirkman, S., Middleton‐Dalby, C., & Joshi, K. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2463975
“CGI-S is a well-validated measure that has been found to correlate well with a number of other standardized measures of depression severity, including the Montgomery–Åsberg Depression Rating Scale, in clinical trials for esketamine 27 .”
Mahmood, S., Tan, X. W., Chen, B., & Phern Chern, T. O. R. (2026) · Journal of Ect · doi:10.1097/yct.0000000000001207
Kim, H., Kwak, E., Lee, D., Lee, S., Lee, D., Ko, S. J., Baik, M., Paik, J., Sim, M., & Jung, S. J. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e165
Okuhira, K., Takahashi, S., Funai, S., Uenishi, Y., Ishida, T., & Kimoto, S. (2026) · Journal of Ect · doi:10.1097/yct.0000000000001343
Metadata
- Authors
- Morrens, J., Mathews, M., Popova, V., Borentain, S., Rive, B., Gonzalez Martin Moro, B., Jamieson, C., & Zhang, Q.
- Affiliations
- Janssen (Belgium) (BE)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Zhang, Qiaoyi
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2022-06
- Volume
- Volume 18
- Pages
- 1127-1132
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC9189368
- OpenAlex
- W4281790437
- Cited by
- 24
- References
- 22
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 2
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- treatment-resistant depression, esketamine nasal spray, Montgomery-Asberg Depression Rating Scale, flexible dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.